Form 4: Quantum-Si Inc. Executive Receives Stock Grant

Todd C. Bennett, Chief Commercial Officer of Quantum-Si Inc., was granted 208,333 shares of Class A Common Stock in the form of restricted stock units.

Summary

• Todd C. Bennett, the Chief Commercial Officer of Quantum-Si Inc., received a grant of 208,333 shares of Class A Common Stock on March 12, 2025.
• The grant is in the form of restricted stock units (RSUs), where each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs will vest in 16 equal quarterly installments starting on September 20, 2025, subject to continued service through each vesting date.
• Following the transaction, Bennett directly owns 718,485 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. There are no explicitly negative aspects mentioned.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing long-term performance and commitment to the company.
• The vesting schedule encourages continued service and dedication from the Chief Commercial Officer.

Risks

• The value of the RSUs is dependent on the future performance of Quantum-Si Inc.'s stock, which is subject to market risks and company-specific factors.
• If the executive leaves the company before the RSUs fully vest, a portion of the grant may be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Executive compensation through stock grants is a common practice in the technology and biotechnology industries to attract and retain talent, aligning their interests with shareholder value.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the biotech industry, often used by companies like Illumina, Pacific Biosciences, and Bio-Rad Laboratories.
• The vesting schedule of 16 quarterly installments is a fairly standard approach to ensure long-term commitment, similar to practices observed in other publicly traded companies.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the Chief Commercial Officer to drive company growth and increase shareholder value.
• Employees may see the grant as a positive sign of the company's commitment to its leadership team.

Key Dates